Monday, November 9, 2026

FOSUM and "NOVO BANCO" Negotiations Failed: Sale Postponed Until After Country's National Elections

Negotiations between Novo Banco and potential buyers Apollo, Anbang, and Fosun collapsed in September 2015, with Fosun's final €1.5 billion offer falling short of Banco de Portugal's expectations. The sale was postponed until after Portugal's national elections.

LM Salvado
LM Salvado

September 11, 2015

Novo Banco sale postponed.
Negotiations have failed between Novo Banco and its buyers Apollo, Anbang, and Fosun. Rumors seem to indicate Banco de Portugal to re-enter negotiations with Apollo before the final decision to postpone the sale to 2016. The last standing bid offer from the Chinese Fosun company was 1.5 billion Euros ($1.7 billion) that was about half the required original offer amount from Banco de Portugal. Banco de Portugal had previously stated there is no hurry in accepting low offers and is prepared to postpone the deal till after the country's next national elections. Novo Banco was created in August 2014 to rescue assets and liabilities from the debts of Banco Espírito Santo. The bank was held by a resolution fund by Portuguese banks with the Banco de Portugal supervision. In an interview to the Portuguese daily "Jornal de Negócios", the President of Millennium BCP, Nuno Amado, said that "the delay in Novo Banco sale may be positive" and "speeding up the sale is not a good idea." Millennium BCP is one of the banks holding the Novo Banco resolution fund.
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com